On Nov 08, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals (JAZZ.US)$, with price targets ranging from $130 to $230.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $140.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $200 to $190.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $120 to $130.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $200 to $195.
Needham analyst Ami Fadia maintains with a buy rating, and maintains the target price at $207.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals reported third-quarter revenue in line with expectations and a considerable non-GAAP net income beat, despite facing short-term challenges affecting the Rylaze brand. Overall, the third-quarter results were deemed 'solid.' The company is perceived to be trading at significantly low multiples, while still promising mid-single digit revenue growth and high-single digit earnings growth on a compound annual basis.
Jazz Pharmaceuticals' third quarter revenue outperformance was propelled by robust growth in key products such as Xywav and Epidiolex. However, Rylaze experienced a temporary setback due to updates in the treatment protocol.
The firm noted that Jazz Pharmaceuticals' total Q3 revenue surpassed expectations, bolstered by strong performance from products such as Xywav, Epidiolex, Defitelio, and Zepzelca.
Here are the latest investment ratings and price targets for $Jazz Pharmaceuticals (JAZZ.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
